Mimetas

Activities: Analysis

Trending Articles

  1. Catalent Boston adds to oral spray drying capacity to support late-stage clinical trials and commercialisation Catalent, the leading provider of oral drug development solutions, bioavailability enhancing technologies and flexible manufacturing, has completed a series of upgrades to its...
  2. £20m Scottish oligonucleotide manufacturing innovation centre now under construction The centre will act as an innovation centre, assisting in the development and optimisation of oligonucleotide manufacturing processes, while also bolstering the UK's...
  3. Novo Nordisk invests DKK 8.5bn into new Danish modular production site This is the first time this century that Novo Nordisk has invested into its Danish production capabilities, with the site being capable of manufacturing product types within...
  4. Scinai Immunotherapeutics establishes Delaware-based US CDMO subsidiary The biopharmaceutical company now operates contract development and manufacturing services in both Jerusalem and Delaware
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535 Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

Related Content

Research & Development

MIMETAS and Yamaha Motor Sign Joint Marketing Agreement Aimed at Advancing Therapeutic Development

Both companies will collaborate to develop innovative applications of the CELL HANDLER in combination with MIMETAS’ 3D tissue models
Research & Development

MIMETAS develops high-throughput gut-on-a-chip technology

MIMETAS, in collaboration with the pharmaceutical company Roche, has developed a novel organ-on-a-chip system that supports evaluation of intestinal permeability in perfused 3-D gut tubules in high throughput under exposure to pharmacological compounds, the results of the research were published in <i>Nature Communications</i>
Finance

Mimetas receives US$1.6m in funding to develop organ-on-a-chip neurotoxicity models

Aims to improve existing tests and reduce experimentation on animals
Subscribe now